Evidence map›Paper›PMID 34754638›Full record

ArticleCureus2021

Evaluation of Automated Treatment Planning and Organ Dose Prediction for Lung Stereotactic Body Radiotherapy.

Zi Ouyang, Tingliang Zhuang, Gaurav Marwaha, Matthew D Kolar, Peng Qi, Gregory M Videtic, Kevin L Stephans, Ping Xia

Abstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Planning issues on linac-based stereotactic radiotherapy.World journal of clinical cases · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zi OuyangDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Tingliang ZhuangDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Gaurav MarwahaDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Matthew D KolarDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Peng QiDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Gregory M VideticDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Kevin L StephansDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.
Ping XiaDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposesTo evaluate whether the auto-planning (AP) module can achieve clinically acceptable treatment plans for lung stereotactic body radiotherapy (SBRT) and to evaluate the effectiveness of a dose prediction model.

methodsTwenty lung SBRT cases planned manually with 50 Gy in five fractions were replanned using the Pinnacle (Philips Radiation Oncology Systems, Fitchburg, WI) AP module according to the dose constraint tables from the Radiation Therapy Oncology Group (RTOG) 0813 protocol. Doses to the organs at risk (OAR) were compared between the manual and AP plans. Using a dose prediction model from a commercial product, PlanIQ (Sun Nuclear Corporation, Melbourne, FL), we also compared OAR doses from AP plans with predicted doses.

resultsAll manual and AP plans achieved clinically required dose coverage to the target volumes. The AP plans achieved equal or better OAR sparing when compared to the manual plans, most noticeable in the maximum doses of the spinal cord, ipsilateral brachial plexus, esophagus, and trachea. Predicted doses to the heart, esophagus, and trachea were highly correlated with the doses of these OARs from the AP plans with the highest correlation coefficient of 0.911, 0.823, and 0.803, respectively.

conclusionAuto-planning for lung SBRT improved OAR sparing while keeping the same dose coverage to the tumor. The dose prediction model can provide useful planning dose guidance.

Indexed as

autoplandose predictionrtog 0813sbrttreatment planning

Identifiers

PMID34754638
PMCPMC8569686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.